

**SP140 Antibody (Center) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP12872c****Specification**

---

**SP140 Antibody (Center) Blocking peptide - Product Information**Primary Accession [Q13342](#)**SP140 Antibody (Center) Blocking peptide - Additional Information****Gene ID** 11262**Other Names**

Nuclear body protein SP140 {ECO:0000312|HGNC:HGNC:17133}, Lymphoid-restricted homolog of Sp100, LYSp100, Nuclear autoantigen Sp-140, Speckled 140 kDa, SP140 ([http://www.genenames.org/cgi-bin/gene\\_symbol\\_report?hgnc\\_id=17133](http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=17133))  
target="\_blank">HGNC:17133</a>)

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SP140 Antibody (Center) Blocking peptide - Protein Information****Name** SP140 ([HGNC:17133](#))**Function**

Component of the nuclear body, also known as nuclear domain 10, PML oncogenic domain, and KR body (PubMed:<http://www.uniprot.org/citations/8910577>)  
target="\_blank">8910577</a>). May be involved in the pathogenesis of acute promyelocytic leukemia and viral infection (PubMed:<http://www.uniprot.org/citations/8910577>)  
target="\_blank">8910577</a>). May play a role in chromatin-mediated regulation of gene expression although it does not bind to histone H3 tails (PubMed:<http://www.uniprot.org/citations/24267382>)  
target="\_blank">24267382</a>).

**Cellular Location**

Nucleus. Nucleus, PML body Cytoplasm. Note=Localized to nuclear structures termed LANDS, for LYSp100-associated nuclear domains. LANDS are globular, electron-dense structures most often found in the nucleoplasm, but also found at the nuclear membrane and in the cytoplasm, suggesting that these structures may traffic between the cytoplasm and the nucleus (PubMed:8695863). Also colocalizes with PML in a subset of PML nuclear bodies (PubMed:8910577)

**Tissue Location**

High levels in spleen and peripheral blood leukocytes, much lower levels in tonsils, thymus, prostate, ovary, small intestine, and colon (PubMed:8695863, PubMed:8910577). Very low levels in heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas (PubMed:8910577). Not detected in brain, liver and muscle (PubMed:8695863).

**SP140 Antibody (Center) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**SP140 Antibody (Center) Blocking peptide - Images****SP140 Antibody (Center) Blocking peptide - Background**

Component of the nuclear body, also known as nuclear domain 10, PML oncogenic domain, and KR body. May be involved in the pathogenesis of acute promyelocytic leukemia and viral infection.

**SP140 Antibody (Center) Blocking peptide - References**

Slager, S.L., et al. Cancer Epidemiol. Biomarkers Prev. 19(4):1098-1102(2010)Di Bernardo, M.C., et al. Nat. Genet. 40(10):1204-1210(2008)Madani, N., et al. J. Virol. 76(21):11133-11138(2002)Bloch, D.B., et al. J. Biol. Chem. 271(46):29198-29204(1996)Dent, A.L., et al. Blood 88(4):1423-1426(1996)